Valuation : Sutro Biopharma, Inc.

Market Cap 35Cr 30Cr 28Cr 26Cr 48Cr 3.26TCr 48Cr 332.15Cr 128.91Cr 1.67TCr 129.63Cr 126.8Cr 5.48TCr P/E 2026 *
-2.53x
P/E 2027 * -3.15x
Enterprise Value 35Cr 30Cr 28Cr 26Cr 48Cr 3.26TCr 48Cr 332.15Cr 128.91Cr 1.67TCr 129.63Cr 126.8Cr 5.48TCr EV / Sales 2026 *
6.7x
EV / Sales 2027 * 10.9x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-2.81%
1 week-5.27%
Current month+0.30%
1 month-19.12%
3 months-16.91%
6 months-1.19%
Current year+75.45%
1 week 19.46
Extreme 19.46
21.68
1 month 18.36
Extreme 18.365
26.35
Current year 10.15
Extreme 10.15
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 13/03/2025
Director of Finance/CFO 53 02/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2026
Director TitleAgeSince
Director/Board Member 70 01/08/2009
Director/Board Member 67 01/02/2017
Director/Board Member 51 25/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
02/06/26 Exercice

Chief Financial Officer

5,000 0.0302%
04/03/26 Exercice

Chief Administrative Officer

1,627 0.0099%
04/03/26 Exercice

Chief Executive Officer

1,858 0.0113%
Change 5-day change 1-year change 3-year change Capi.($)
-2.81%-5.27%+113.46%-53.86% 35Cr
+1.03%-3.11%+39.80%+94.60% 6.82TCr
+1.62%+0.33%+48.61%+89.64% 6.42TCr
+1.21%-0.92%-15.18%+367.35% 2.65TCr
+1.20%-8.26%+2.63%-15.36% 2.56TCr
+1.30%+0.74%+31.66%-18.33% 1.99TCr
-0.38%-12.42%+224.86%+373.18% 1.71TCr
+0.65%-5.83%+1.44%+544.44% 1.49TCr
+1.22%+3.10%+55.57%+159.72% 1.41TCr
+0.27%+0.77%+24.51%+194.32% 1.24TCr
Average +0.53%-3.66%+52.74%+173.57% 2.63TCr
Weighted average by Cap. +1.08%-3.01%+42.26%+153.27%

Financials

2026 *2027 *
Net sales 5.16Cr 4.45Cr 4.19Cr 3.82Cr 7.14Cr 487Cr 7.19Cr 50Cr 19Cr 248.99Cr 19Cr 19Cr 817.92Cr 3.16Cr 2.73Cr 2.57Cr 2.34Cr 4.37Cr 298.43Cr 4.41Cr 30Cr 12Cr 152.58Cr 12Cr 12Cr 501.22Cr
Net income -13Cr -11Cr -11Cr -9.59Cr -18Cr -1.22TCr -18Cr -124.61Cr -48Cr -625.53Cr -49Cr -48Cr -2.05TCr -14Cr -12Cr -11Cr -10Cr -19Cr -1.33TCr -20Cr -135.41Cr -53Cr -679.71Cr -53Cr -52Cr -2.23TCr
Net Debt - -
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
128
Date Price Change Volume
02/26/02 $20.30 -2.50% 60,152
01/26/01 $20.82 +2.87% 1,29,483
31/26/31 $20.24 -1.03% 1,69,297
28/26/28 $20.45 -4.04% 1,43,817
27/26/27 $21.31 -0.56% 92,167
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
20.82USD
Average target price
47.23USD
Spread / Average Target
+126.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STRO Stock